NDAORALSOLUTION
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
LYRICA (pregabalin) by Viatris is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2010.
Drug data last refreshed 15h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA (pregabalin) is an oral small-molecule pain and seizure medication that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces pro-nociceptive neurotransmitter release in the spinal cord and modulates descending pain pathways, making it effective for neuropathic pain, fibromyalgia, and seizure disorders. The drug does not act as a GABA agonist despite its structural similarity to GABA.
$0.072BPart D
LOE ApproachingProduct approaching loss of exclusivity with stable Part D presence; commercial teams will shift focus to generic transition and cost management strategies.
Mechanism of Action
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.